Literature DB >> 31303562

The immunological roles in acute-on-chronic liver failure: An update.

Ping Chen1, Yun-Yun Wang1, Chao Chen1, Jun Guan1, Hai-Hong Zhu1, Zhi Chen2.   

Abstract

BACKGROUND: Acute-on-chronic liver failure (ACLF) refers to the acute deterioration of liver function that occurs in patients with chronic liver disease. ACLF is characterized by acute decompensation, organ failure and high short-term mortality. Numerous studies have been conducted and remarkable progress has been made regarding the pathophysiology and pathogenesis of this disease in the last decade. The present review was to summarize the advances in this field. DATA SOURCES: A comprehensive search in PubMed and EMBASE was conducted using the medical subject words "acute-on-chronic liver failure", "ACLF", "pathogenesis", "predictors", and "immunotherapy" combined with free text terms such as "systemic inflammation" and "immune paralysis". Relevant papers published before October 31, 2018, were included.
RESULTS: ACLF has two marked pathophysiological features, namely, excessive systemic inflammation and susceptibility to infection. The systemic inflammation is mainly manifested by a significant increase in the levels of plasma pro-inflammatory factors, leukocyte count and C-reactive protein. The underlying mechanisms are unclear and may be associated with decreased immune inhibitory cells, abnormal expression of cell surface molecules and intracellular regulatory pathways in immune cells and increased damage-associated molecular patterns in circulation. However, the main cause of susceptibility to infection is immune paralysis. Immunological paralysis is characterized by an attenuated activity of immune cells. The mechanisms are related to elevations of immune inhibitory cells and the concentration of plasma anti-inflammatory molecules. Some immune biological indicators, such as soluble CD163, are used to explore the pathogenesis and prognosis of the disease, and some immunotherapies, such as glucocorticoids and granulocyte colony-stimulating factor, are effective on ACLF.
CONCLUSIONS: Overwhelming systemic inflammation and susceptibility to infection are two key features of ACLF. A better understanding of the state of a patient's immune system will help to guide immunotherapy for ACLF.
Copyright © 2019 First Affiliated Hospital, Zhejiang University School of Medicine in China. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute-on-chronic liver failure; Immunotherapy; Pathogenesis; Predictors

Mesh:

Substances:

Year:  2019        PMID: 31303562     DOI: 10.1016/j.hbpd.2019.07.003

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  14 in total

1.  Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  Guojun Shen; Shuilin Sun; Jie Huang; Haohui Deng; Ying Xu; Zhanhui Wang; Xiong Tang; Xiaodong Gong
Journal:  Hepatol Int       Date:  2019-12-23       Impact factor: 6.047

2.  Granulocyte Colony-Stimulating Factor Accelerates the Recovery of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure by Promoting M2-Like Transition of Monocytes.

Authors:  Jingjing Tong; Hongmin Wang; Xiang Xu; Zhihong Wan; Hongbin Fang; Jing Chen; Xiuying Mu; Zifeng Liu; Jing Chen; Haibin Su; Xiaoyan Liu; Chen Li; Xiaowen Huang; Jinhua Hu
Journal:  Front Immunol       Date:  2022-05-16       Impact factor: 8.786

Review 3.  The Management of Glucocorticoid Therapy in Liver Failure.

Authors:  Ran Xue; Qinghua Meng
Journal:  Front Immunol       Date:  2019-10-23       Impact factor: 7.561

4.  The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial.

Authors:  Lin Jia; Ran Xue; Yueke Zhu; Juan Zhao; Juan Li; Wei-Ping He; Xiao-Mei Wang; Zhong-Hui Duan; Mei-Xin Ren; Hai-Xia Liu; Hui-Chun Xing; Qing-Hua Meng
Journal:  BMC Med       Date:  2020-12-08       Impact factor: 8.775

Review 5.  Uncertainty in the impact of liver support systems in acute-on-chronic liver failure: a systematic review and network meta-analysis.

Authors:  Klementina Ocskay; Anna Kanjo; Noémi Gede; Zsolt Szakács; Gabriella Pár; Bálint Erőss; Jan Stange; Steffen Mitzner; Péter Hegyi; Zsolt Molnár
Journal:  Ann Intensive Care       Date:  2021-01-18       Impact factor: 6.925

6.  Lower testosterone levels predict increasing severity and worse outcomes of hepatitis B virus-related acute-on-chronic liver failure in males.

Authors:  Yandi Huang; Dong Yan; Huafen Zhang; Bin Lou; Ren Yan; Yifan Yao; Minya Dong; Donglei Yang; Feifei Lv; Yu Chen
Journal:  BMC Gastroenterol       Date:  2021-12-06       Impact factor: 3.067

Review 7.  Glucocorticoid Treatment Strategies in Liver Failure.

Authors:  Chao Ye; Wenyuan Li; Lei Li; Kaiguang Zhang
Journal:  Front Immunol       Date:  2022-03-16       Impact factor: 7.561

Review 8.  Role of immune dysfunction in drug induced liver injury.

Authors:  Chandrashekaran Girish; Sukumaran Sanjay
Journal:  World J Hepatol       Date:  2021-11-27

9.  Soluble factors and suppressive monocytes can predict early development of sepsis in acute-on-chronic liver failure.

Authors:  Pushpa Yadav; Nirupama Trehanpati; Rakhi Maiwall; Rashi Sehgal; Ravinder Singh; Mojahidul Islam; Rakesh Kumar Jagdish; Rajan Vijayaraghavan; Deepanshu Maheshwari; Sadam Bhat; Pratibha Kale; Anupam Kumar; Sukriti Baweja; Guresh Kumar; Gayatri Ramakrishna; Shiv K Sarin
Journal:  Hepatol Commun       Date:  2022-05-02

10.  Ammonia predicts poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure.

Authors:  JinFei Zhang; XiaoLu Liu; Bo Ye; Hui Chen
Journal:  J Clin Lab Anal       Date:  2020-09-11       Impact factor: 3.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.